Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To characterize the levodopa pharmacokinetics and safety/tolerability of ABBV-951 in a first-in-human study following continuous subcutaneous (SC) infusion

Next Previous
Trial Profile

To characterize the levodopa pharmacokinetics and safety/tolerability of ABBV-951 in a first-in-human study following continuous subcutaneous (SC) infusion

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foscarbidopa/Foslevodopa (Primary) ; Levodopa/carbidopa; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 09 Jan 2024 According to an AbbVie media release, company announced the launch of PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement).The launch was supported by three studies:M15-741,M15-736 study & Phase 1 pharmacokinetic comparability study.
  • 27 Apr 2023 Results (n=20) assessing to compare levodopa pharmacokinetics following subcutaneous infusion of foslevodopa/foscarbidopa and jejunal delivery of Levodopa-Carbidopa Intestinal Gel both administered for 24 hours in healthy volunteers, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top